Abstract
AbstractAn extended action fostemsavir (FTR) lipid nanoparticle (LNP) formulation prevents human immunodeficiency virus type one (HIV-1) infection. This FTR formulation establishes a drug depot in monocyte-derived macrophages that extend the drug’s plasma residence time. The LNP’s physicochemical properties improve FTR’s antiretroviral activities, which are linked to the drug’s ability to withstand fluid flow forces and levels of drug cellular internalization. Each is, in measure, dependent on PEGylated lipid composition and flow rate ratios affecting the size, polydispersity, shape, zeta potential, stability, biodistribution, and antiretroviral efficacy. The FTR LNP physicochemical properties enable the drug-particle’s extended actions.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Publisher
Springer Science and Business Media LLC
Reference79 articles.
1. Global A. Update. Confronting Inequalities-Lessons for pandemic responses from 40 years of AIDS. (Geneva, Switzerland, UNAIDS Joint United Nations Programme on HIV/AIDS, 2021).
2. Yehia, B. R., Fleishman, J. A., Metlay, J. P., Moore, R. D. & Gebo, K. A. Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. Jama 308, 339–342 (2012).
3. Kroeze, S. et al. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. Aids 32, 1043–1051 (2018).
4. Priest, J., Hulbert, E., Gilliam, B. L., Burton, T., editors. Characterization of Heavily Treatment-Experienced People With HIV and Impact on Health Care Resource Utilization in US Commercial and Medicare Advantage Health Plans. Open forum infectious diseases. (Oxford University Press US, 2021).
5. Markham, A. Fostemsavir: First Approval. Drugs 80, 1485–1490 (2020).